Company Registration No. SC438418 (Scotland)
BAIRD'S PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2018
PAGES FOR FILING WITH REGISTRAR
BAIRD'S PHARMACY LIMITED
COMPANY INFORMATION
Directors
Nicol Baird
Michelle Baird
Robert Baird
Myrtle Baird
Secretary
Michelle Baird
Company number
SC438418
Registered office
302 - 308 Clifton Road
ABERDEEN
AB24 4HP
Accountants
Johnston Carmichael LLP
Strathdeveron House
Steven Road
Huntly
AB54 8SX
BAIRD'S PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 9
BAIRD'S PHARMACY LIMITED
BALANCE SHEET
AS AT 31 JANUARY 2018
31 January 2018
- 1 -
2018
2017
Notes
£
£
£
£
Fixed assets
Goodwill
4
420,000
983,500
Tangible assets
5
989,695
943,337
Investments
6
2,368,116
-
3,777,811
1,926,837
Current assets
Stocks
254,112
191,827
Debtors
7
695,550
556,356
Cash at bank and in hand
404,502
264,223
1,354,164
1,012,406
Creditors: amounts falling due within one year
8
(3,034,331)
(2,335,413)
Net current liabilities
(1,680,167)
(1,323,007)
Total assets less current liabilities
2,097,644
603,830
Creditors: amounts falling due after more than one year
9
(2,399,818)
(906,304)
Net liabilities
(302,174)
(302,474)
Capital and reserves
Called up share capital
10
150
150
Profit and loss reserves
(302,324)
(302,624)
Total equity
(302,174)
(302,474)

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 January 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

BAIRD'S PHARMACY LIMITED
BALANCE SHEET (CONTINUED)
AS AT 31 JANUARY 2018
31 January 2018
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 18 October 2018 and are signed on its behalf by:
Nicol Baird
Director
Company Registration No. SC438418
BAIRD'S PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2018
- 3 -
1
Accounting policies
Company information

Baird's Pharmacy Limited is a private company limited by shares incorporated in Scotland. The registered office and business address is 302-304 Clifton Road, Aberdeen, AB24 4HP.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the company as an individual entity and not about its group.

1.2
Going concern

The balance sheet shows a net deficit position as at 31 January 2018. The directors have agreed to support the business to ensure that all liabilities are met as they fall due therefore they believe that the going concern status is appropriate.

1.3
Turnover

Turnover represents amounts receivable from the sale of products from a dispensing chemist, net of VAT.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 5 years.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

BAIRD'S PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2018
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Land and buildings Freehold
- 2% straight line
Leasehold improvements
- 10% straight line
Plant and machinery
- 20% straight line
Computer equipment
- 33.33% straight line
Motor vehicles
- 25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises purchase price.

1.9
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks.

1.10
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs. Basic financial assets are assessed for indicators of impairment at each financial reporting date with any resulting impairment recognised through profit or loss.

BAIRD'S PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2018
1
Accounting policies
(Continued)
- 5 -
Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans, are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.11
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to the profit and loss account so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease.

BAIRD'S PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2018
1
Accounting policies
(Continued)
- 6 -
1.15
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in the profit and loss account for the period.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was 35 (2017 - 36).

3
Dividends
2018
2017
£
£
Interim paid
41,300
32,500

At the time that the above dividends were authorised, the directors were not aware that there were insufficient profits available for distribution.

4
Intangible fixed assets
Goodwill
£
Cost
At 1 February 2017 and 31 January 2018
2,817,500
Amortisation and impairment
At 1 February 2017
1,834,000
Amortisation charged for the year
563,500
At 31 January 2018
2,397,500
Carrying amount
At 31 January 2018
420,000
At 31 January 2017
983,500
BAIRD'S PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2018
- 7 -
5
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 February 2017
647,193
476,376
1,123,569
Additions
156,787
10,529
167,316
Disposals
-
(2,600)
(2,600)
At 31 January 2018
803,980
484,305
1,288,285
Depreciation and impairment
At 1 February 2017
26,633
153,599
180,232
Depreciation charged in the year
24,506
94,738
119,244
Eliminated in respect of disposals
-
(886)
(886)
At 31 January 2018
51,139
247,451
298,590
Carrying amount
At 31 January 2018
752,841
236,854
989,695
At 31 January 2017
620,560
322,777
943,337
6
Fixed asset investments
2018
2017
£
£
Investments
2,368,116
-

 

Movements in fixed asset investments
Shares in group undertakings
£
Cost or valuation
At 1 February 2017
-
Additions
2,368,116
At 31 January 2018
2,368,116
Carrying amount
At 31 January 2018
2,368,116
At 31 January 2017
-
BAIRD'S PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2018
- 8 -
7
Debtors
2018
2017
Amounts falling due within one year:
£
£
Trade debtors
602,640
368,088
Corporation tax recoverable
-
12,855
Other debtors
92,910
175,413
695,550
556,356
8
Creditors: amounts falling due within one year
2018
2017
Notes
£
£
Bank loans and overdrafts
288,308
88,207
Obligations under finance leases
41,963
65,735
Trade creditors
620,104
481,009
Amounts due to group undertakings
186,807
-
Corporation tax
-
3,337
Other taxation and social security
7,415
7,782
Other creditors
1,790,086
1,678,258
Accruals and deferred income
99,648
11,085
3,034,331
2,335,413

The bank loans and overdraft are secured by a fixed charge over certain land and buildings, a floating charge over all assets of the company and a share pledge in respect of the issued share capital of the company.

 

Obligations under finance leases are secured by fixed charges over the assets to which they relate.

9
Creditors: amounts falling due after more than one year
2018
2017
Notes
£
£
Bank loans and overdrafts
2,373,764
838,287
Obligations under finance leases
26,054
68,017
2,399,818
906,304

The bank loan is secured by a fixed charged over certain land and buildings, a floating charge over all assets of the company and a share pledge in respect of the issued share capital of the company.

 

Obligations under finance leases are secured by fixed charges over the assets to which they relate.

Amounts included above which fall due after five years are as follows:
Payable by instalments
-
485,460
BAIRD'S PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2018
- 9 -
10
Called up share capital
2018
2017
£
£
Ordinary share capital
Issued and fully paid
100 Ordinary A shares of £1 each
100
100
50 Ordinary B shares of £1 each
50
50
150
150
11
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2018
2017
£
£
204,000
224,400

The above represents the commitment remaining under a 15 year property lease.

12
Related party transactions
Transactions with related parties

The directors are materially interested in an unincorporated business. Included in creditors at the year end is £1,264,942 (2016 - £1,461,266) due to that business. No interest is payable on this balance and there are no fixed terms of repayment.

2018-01-312017-02-01falseCCH SoftwareCCH Accounts Production 2018.220No description of principal activityNicol BairdMichelle BairdRobert BairdMyrtle BairdMichelle BairdSC4384182017-02-012018-01-31SC438418bus:Director12017-02-012018-01-31SC438418bus:CompanySecretaryDirector12017-02-012018-01-31SC438418bus:Director32017-02-012018-01-31SC438418bus:Director42017-02-012018-01-31SC438418bus:Director22017-02-012018-01-31SC438418bus:CompanySecretary12017-02-012018-01-31SC438418bus:RegisteredOffice2017-02-012018-01-31SC4384182018-01-31SC438418core:Goodwill2018-01-31SC438418core:Goodwill2017-01-31SC438418core:NetGoodwill2018-01-31SC438418core:NetGoodwill2017-01-31SC4384182017-01-31SC438418core:LandBuildings2018-01-31SC438418core:OtherPropertyPlantEquipment2018-01-31SC438418core:LandBuildings2017-01-31SC438418core:OtherPropertyPlantEquipment2017-01-31SC438418core:CurrentFinancialInstruments2018-01-31SC438418core:CurrentFinancialInstruments2017-01-31SC438418core:WithinOneYear2018-01-31SC438418core:WithinOneYear2017-01-31SC438418core:AfterOneYear2018-01-31SC438418core:AfterOneYear2017-01-31SC438418core:Non-currentFinancialInstruments2018-01-31SC438418core:Non-currentFinancialInstruments2017-01-31SC438418core:ShareCapital2018-01-31SC438418core:ShareCapital2017-01-31SC438418core:RetainedEarningsAccumulatedLosses2018-01-31SC438418core:RetainedEarningsAccumulatedLosses2017-01-31SC438418core:ShareCapitalOrdinaryShares2018-01-31SC438418core:ShareCapitalOrdinaryShares2017-01-31SC438418core:Goodwill2017-02-012018-01-31SC438418core:LandBuildingscore:OwnedOrFreeholdAssets2017-02-012018-01-31SC438418core:LeaseholdImprovementscore:LeasedAssetsHeldAsLessee2017-02-012018-01-31SC438418core:PlantMachinery2017-02-012018-01-31SC438418core:ComputerEquipment2017-02-012018-01-31SC438418core:MotorVehicles2017-02-012018-01-31SC438418core:NetGoodwill2017-01-31SC438418core:NetGoodwill2017-02-012018-01-31SC438418core:LandBuildings2017-01-31SC438418core:OtherPropertyPlantEquipment2017-01-31SC4384182017-01-31SC438418core:LandBuildings2017-02-012018-01-31SC438418core:OtherPropertyPlantEquipment2017-02-012018-01-31SC438418bus:PrivateLimitedCompanyLtd2017-02-012018-01-31SC438418bus:FRS1022017-02-012018-01-31SC438418bus:AuditExemptWithAccountantsReport2017-02-012018-01-31SC438418bus:SmallCompaniesRegimeForAccounts2017-02-012018-01-31SC438418bus:FullAccounts2017-02-012018-01-31xbrli:purexbrli:sharesiso4217:GBP